Lurasidonum

Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.

**Lurasidonum**
Cognitores
ChemSpider	184739
PubChem	213046
DrugBank	DB08815
Natura chemica


Formula chemica	C ₂₈H ₃₆N ₄O ₂S
Massa molaris	492.68 g/mol
Natura pharmacologica
Codex ATC	N05AE05 (WHO)
Semivita biologica	18-40 h
Metabolismus	iecore (hepaticus): CYP3A4
Excretio	faecibus 67-80% renibus 9-19%
Ad usum therapeuticum
Applicatio	per os
DDD	60 mg (•HCl)
MedlinePlus	a611016 (Anglice)

Lurasidonum est medicamentum pharmaceuticum et antipsychoticum atypicum ad schizophreniam et ad conturbationem bipolarem^[1] tractandam.

Lurasidonum imprimis receptoria D2 et 5HT-2_A obsidet. Excretio Lurasidoni maiore in parte per biles et faecibus fit.

Natura Lurasidoni

Natura chemica

Lurasidonum est piperazinum. Nomen chemicum (IUPAC) est (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benz-iso-thiazolo-3-yl)-piperazino-1-ylmethyl]-cyclohexylmethylo}-hexahydro-1H-4,7-methan-iso-indol-1,3-dionum. Massa molaris est 492.68 g/mol.

Natura pharmacologica

Lurasidonum est medicamentum cum virtutibus antipsychoticis et effectus therapeuticos in conturbationem bipolarem tractando affert. Codex ATC est N05AE05 (WHO).

Pharmacodynamica

Recept.	Affinitas ligandi, K_i (nM)^[2]	Actio
D₁	262	incogn.
D₂	1.68	antagonista
D₃	115.7	antagonista
D_4.4	30	incogn.
5-HT_2A	2.03	antagonista
5-HT₇	0.495	antagonista
NET	>10,000	-

Substantia effectus receptoriorum imprimis et dopaminergici D2 et serotonergici_2A ostendit.

Pharmacocinetica

Tempus semivitae biologicum $t_{\frac {1}{2}}$ .^[3] inter 18 et 40 horas variat. Excretio imprimis per biles et faecibus (67-80%), minore in parte per renibus (9-19%) fit.

Usus Lurasidoni

Dosis diurna definita (DDD) est 60 mg per die p.o. (hydrochloridum)^[4]; dosis initialis 20-40 mg, die semel consumatum, commendatur.

Nexus interni

Notae

↑ Ketter T. A., Sarma K. (Mai 2016). "Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study". Depression and anxiety 33 (5): 424-34
↑ https://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php
↑ http://goldbook.iupac.org/B00658.html
↑ Systema classificationis Anatomicum Therapeuticum Chemicumque, cap. N05AE cum Lurasidoni referentia

Nexus externi

Lurasidoni monographia (Anglice)

[1] Ketter T. A., Sarma K. (Mai 2016). "Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study". Depression and anxiety 33 (5): 424-34

[2] ttps://web.archive.org/web/20131108013656/http://pdsp.med.unc.edu/pdsp.php

[3] ttp://goldbook.iupac.org/B00658.html

[4] Systema classificationis Anatomicum Therapeuticum Chemicumque, cap. N05AE cum Lurasidoni referentia

[1]

[2]

[3]

[4]